Print this page
Cole
-
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Phase II Dose Optimization Study of Platinum/Etoposide Plus Ivonescimab (CEI) as First-Line Treatment of Extensive-Stage Small Cell Lung Cancer.
Protocol: 032509Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO).
Protocol: 092305Principal Investigator:
- Sarah Weiss
Applicable Disease Sites: Melanoma, Skin -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
Characterization of Brain Dysfunction During Development in Survivors of Childhood Acute Lymphoblastic Leukemia.
Protocol: 112002Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Leukemia, not otherwise specified -
A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors
Protocol: 112307Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Any Site -
A bilingual virtually-based intervention (PEDALL) for the prevention of weight gain in childhood ALL patients considering key genetic and sociodemographic risk factors
Protocol: 112307Principal Investigator:
- Peter D. Cole
Applicable Disease Sites: Any Site